Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD

Neurology

Volumn 56, Issue 11, 2001, Pages 1559-1564

  Guttman, Mark ^a,b,c   Stewart, D ^a   Hussey, D ^a   Wilson, A ^a   Houle, S ^a   Kish, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; LEVODOPA; PRAMIPEXOLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; HUMAN; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0035849532     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.11.1559     Document Type: Article

References (31)

1. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
2. 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration
3. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels
4. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter
5. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
6. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
7. 3H]mazindol binding sites in rat striatum by dopaminergic agents
8. 2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - An autoradiographic study
9. 123I]β-CIT
10. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's Disease
11. Reproducibility and effect of levodopa on dopamine transporter function measurements: A [18-F]CFT PET study
12. Facile radiolabelling and purification of 2B-[O-[11]CH3]-carbomethoxy-2B-aryltropanes: Radiotracers for the dopamine transporter
13. 18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography
14. PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: Implications for the symptomatic threshold
15. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
16. Regional blood flow in hemiparkinsonism
17. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease
18. The effects of L-dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease
19. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers
20. Synthesis, ligand binding, QSAR and CoMFA study of 3B-(p-substituted phenol) tropane-2B-carboxylic acid methyl esters
21. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter
22. 123I]β-CIT: Pharmacological characterization of brain uptake in nonhuman primates
23. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys
24. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys
25. Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites
26. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease
27. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
28. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
29. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
30. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
31. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease